IMMUNE GLOBULIN INTRAVENOUS
Immune Globulin Intravenous Adverse Events Reported to the FDA Over Time
How are Immune Globulin Intravenous adverse event reports trending over time?
This graph shows volume of adverse events submitted to the FDA by quarter for Immune Globulin Intravenous, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Immune Globulin Intravenous is flagged as the suspect drug causing the adverse event.
Most Common Immune Globulin Intravenous Adverse Events Reported to the FDA
What are the most common Immune Globulin Intravenous adverse events reported to the FDA?
| Neutropenia | 120 (2.73%) |
| Pyrexia | 96 (2.18%) |
| Drug Exposure During Pregnancy | 77 (1.75%) |
| Chills | 64 (1.45%) |
| Headache | 58 (1.32%) |
| Nausea | 58 (1.32%) |
| Drug Ineffective | 55 (1.25%) |
| Infusion Related Reaction | 48 (1.09%) |
| Vomiting | 46 (1.04%) |
| Pulmonary Embolism | 39 (.89%) |
| Haemoglobin Decreased | 38 (.86%) |
 Show More |
Share/Embed Graph Export Data
This graph shows the top adverse events submitted to the FDA for Immune Globulin Intravenous, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Immune Globulin Intravenous is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.
Adverse Event Categories for Immune Globulin Intravenous
What are the most common Immune Globulin Intravenous adverse events reported to the FDA?
| Epidermal And Dermal Conditions | 189 (4.29%) |
| Infections - Pathogen Unspecified | 175 (3.98%) |
| Central Nervous System Vascular | 149 (3.38%) |
| Respiratory | 145 (3.29%) |
| Gastrointestinal Signs | 137 (3.11%) |
| White Blood Cell | 131 (2.98%) |
| Therapeutic And Nontherapeutic Effe... | 118 (2.68%) |
| Neurological | 115 (2.61%) |
| Hematology Investigations | 109 (2.48%) |
| Body Temperature Conditions | 100 (2.27%) |
| Viral Infectious | 94 (2.14%) |
| Show More |
Share/Embed Graph Export Data
This graph shows the top categories of adverse events submitted to the FDA for Immune Globulin Intravenous, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Immune Globulin Intravenous is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.
Common Uses of Immune Globulin Intravenous According to Those Reporting Adverse Events
Why are people taking Immune Globulin Intravenous, according to those reporting adverse events to the FDA?
| Idiopathic Thrombocytopenic Purpura | 388 |
| Drug Use For Unknown Indication | 184 |
| Off Label Use | 87 |
| Kawasakis Disease | 75 |
| Product Used For Unknown Indication | 65 |
| Chronic Inflammatory Demyelinating ... | 42 |
| Show More |
Drug Labels
| Label | Labeler | Effective |
|---|---|---|
| Flebogamma | Instituto Grifols, S.A. | 01-SEP-04 |
| Octagam Immune Globulin (human) | Octapharma AB | 09-SEP-09 |
| Octagam Immune Globulin (human) | Octapharma Pharmazeutika Produktionsgesellschaft m.b.H. | 09-SEP-09 |
| Hepagam B | Cangene bioPharma Inc. | 14-JUN-10 |
| Gammaplex | BioProducts Laboratory | 24-JUN-10 |
| Gammagard S/d | Baxter Healthcare Corporation | 17-JUN-11 |
| Gammagards/d | Baxter Healthcare Corporation | 16-DEC-11 |
| Gammagards/d | Baxter Healthcare Corporation | 16-DEC-11 |
| Gammagards/d | Baxter Healthcare Corporation | 16-DEC-11 |
| Flebogammadif | Instituto Grifols, S.A. | 31-DEC-11 |
| Flebogamma Dif | Instituto Grifols, S.A. | 31-DEC-11 |
| Hepagam B | Cangene bioPharma Inc. | 13-JAN-12 |
| Carimune Nanofiltered | CSL Behring AG | 13-JUL-12 |
| Cytogam | CSL Behring AG | 22-AUG-12 |
| Gammagards/d | Baxter Healthcare Corporation | 03-SEP-12 |
| Gammagards/d | Baxter Healthcare Corporation | 03-SEP-12 |
| Rhophylac | CSL Behring AG | 17-OCT-12 |
| Babybig | CALIFORNIA DEPARTMENT OF PUBLIC HEALTH | 28-JAN-13 |
| Privigen | CSL Behring AG | 14-FEB-13 |
Immune Globulin Intravenous Case Reports
What Immune Globulin Intravenous safety concerns are being reported by doctors and researchers in the medical literature?
About Results
This report contains aggregated drug side effects and adverse events for Immune Globulin Intravenous. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.
DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.
DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.
Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.
Comments
Share your experience with Immune Globulin Intravenous.